Document Detail

CC chemokine CCL5 plays a central role impacting infarct size and post-infarction heart failure in mice.
MedLine Citation:
PMID:  21606075     Owner:  NLM     Status:  Publisher    
Aims The chemokine CCL5 plays a critical role as neutrophil and macrophage activator do in atherosclerosis and myocardial infarction. Thus, we investigated whether the treatment with a neutralizing monoclonal antibody (mAb) to mouse CCL5 would provide therapeutic benefit when provoking a coronary-associated ischaemic event. Methods and Results C57Bl/6 mice were submitted to left coronary artery permanent ligature. Then, various parameters were monitored for up to 21 days. At5 min and 3days after coronary occlusion, mice received one intravenous injection of the rat anti-mouse CCL5 mAb or isotype IgG control. Infarct size was assessed histologically and by measuring serum cardiac troponin I levels. Kinetics of CCL5 tissue expression, leucocyte infiltration, matrix metalloproteinase (MMP) levels, and collagen deposition were histologically assessed. Serum chemokine levels were measured by enzyme-linked immunosorbent assay. Cardiac function and dimensions were assessed by magnetic resonance imaging (MRI). Chronic ischaemia increased both circulating and intracardiac levels of CCL5. At 24 h, treatment with the anti-CCL5 mAb resulted in a smaller infarct size and reduced circulating levels of chemokines. This effect was associated with reduction of neutrophil and macrophage infiltration within the infarcted myocardium. After 3 days of chronic ischaemia, anti-CCL5 mAb treatment reduced cardiac MMP-9. At 7 days, collagen content was significantly lower. At 21 days, neutralizing CCL5 improved mouse survival, cardiac myocyte size, and cardiac function. Conclusion Treatment with anti-CCL5 mAb significantly reduced both infarct size and post-infarction heart failure in a mouse model of chronic cardiac ischaemia. Cardioprotective effects were associated with the reduction of leucocyte recruitment within infarcted hearts.
Fabrizio Montecucco; Vincent Braunersreuther; Sébastien Lenglet; Benedicte M A Delattre; Graziano Pelli; Vanessa Buatois; Florence Guilhot; Katia Galan; Nicolas Vuilleumier; Walter Ferlin; Nicolas Fischer; Jean-Paul Vallée; Marie Kosco-Vilbois; François Mach
Related Documents :
270935 - Limitations of marathon running in the rehabilitation of coronary patients: anatomic an...
19027595 - 3d echocardiography: the present and the future.
2304095 - Incidence of legionella pneumophila infections among oklahoma pulmonary disease patients.
20881485 - Recent advances in cardiac rehabilitation.
7314085 - Myocardial oxygen extraction rate under general anesthesia.
16897145 - Clinical implication of adenosine-stress cardiac magnetic resonance imaging as potentia...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2011-5-23
Journal Detail:
Title:  European heart journal     Volume:  -     ISSN:  1522-9645     ISO Abbreviation:  -     Publication Date:  2011 May 
Date Detail:
Created Date:  2011-5-24     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8006263     Medline TA:  Eur Heart J     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Division of Cardiology, Foundation for Medical Researches, Department of Internal Medicine, University Hospital, Geneva, Switzerland.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  First-degree atrioventricular block is associated with heart failure and death in persons with stabl...
Next Document:  Resistance artery mechanics and composition in angiotensin II-infused mice: effects of cyclooxygenas...